Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Experimental Therapeutics

The Use of the l-Plastin Promoter for Adenoviral-mediated, Tumor-specific Gene Expression in Ovarian and Bladder Cancer Cell Lines

Xue Yan Peng, Jong Ho Won, Thomas Rutherford, Takuma Fujii, Daniel Zelterman, Giuseppi Pizzorno, Eva Sapi, John Leavitt, Barry Kacinski, Ronald Crystal, Peter Schwartz and Albert Deisseroth
Xue Yan Peng
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jong Ho Won
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Rutherford
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takuma Fujii
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Zelterman
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppi Pizzorno
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eva Sapi
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Leavitt
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Kacinski
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald Crystal
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Schwartz
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Albert Deisseroth
Genetic Therapy Program, Yale Cancer Center [X. Y. P., J. H. W., T. F., D. Z., G. P., J. L., A. D.], Medical Oncology Section, Departments of Internal Medicine, Therapeutic Radiology Program [E. S., B. K.], and Obstetrics and Gynecology [T. R., P. S.], Yale University School of Medicine, New Haven, Connecticut 06520, and Cornell Medical School, New York, New York, 10021 [R. C.]
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published June 2001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Toxicity of vectors at varying levels of infected cells. Ovcar-5 (A and B) or CCD (C and D) cell lines were infected at varying MOI (20, 80, and 160) using the Ad-CMV-CD (B and D) or Ad-LP-CD (A and C) adenoviral vectors. The infected cells and noninfected cells were mixed in varying ratios to generate 0, 5, 10, 20, 30, 40, 50, 60, and 100% infected cells. Then cells were seeded in six-well plates and incubated for 5 days in 500 μm 5FC. Then the cells were trypsinized, and surviving cells were counted by trypan blue exclusion.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Study of the toxicity of the control Lac-Z vector versus the CD vector. Cells (2×105) were infected at 0, 5, 20, 40, 80 and 160 MOI of vector with Ad-CMV-CD (A), Ad-Lp-CD (B), Ad-CMV-LacZ (C), Ad-Lp-LacZ (D) vectors for 90 min. Then cells were seeded in six-well plates in duplicate and incubated in 500 μm 5FC for 5 days. The percentage of surviving cells was counted by trypan blue exclusion.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Ovarian organ cultures. Normal ovarian tissue was obtained from patients undergoing abdominal surgical procedures. The tissues were cut into small pieces and cultured in DMEM:Ham’s F12 medium with 10% charcoal-stripped serum. Twenty-four to forty-eight h later, the tissues were infected with vectors for 90 min, washed with PBS, and then incubated for 48 h. Then the tissues were frozen in OCT and sectioned, after which the frozen sections were stained by the X-Gal reaction. Left, no vector; middle, Ad-CMV-LacZ vector; right, Ad-Lp-LacZ vector.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Effect of in vivo injection of tumor nodules with adenoviral vectors. Ovcar-5 (A) or EJ (B) cells (5×106) were injected s.c. into nude mice. After 3 weeks, the tumor nodules were measured. Then, 108 pfu of the Ad-CMV-CD, 108 pfu of the Ad-Lp-CD, or 108 pfu of the Ad-CMV-LacZ vectors were injected into each tumor nodule, and 500 mg/kg of 5FC was given i.p. once a day for 5 days. Seven days later, the tumor nodules were measured again. □ shows tumor volume before viral particles and 5FC treatment; Embedded Image shows the tumor volume 7 days after exposure to viral particles and 5FC treatment.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Vector toxicity to tumor cells and adjacent tissues. Ovcar-5 cells (5x106) were injected s.c. After 3 weeks, 108 pfu of Ad-Lp-CD (right), 108 pfu of Ad-CMV-CD (left), or 108 pfu of Ad-CMV-LacZ (middle) vector were injected into each tumor nodule, and 500 mg/kg 5FC was given i.p. once a day for 5 days. Right (Ad-Lp-CD), most of the tumor cells are necrotic, whereas the adjacent muscle cells have a normal structure. Left (Ad-CMV-CD), after injection with the Ad-CMV-CD vector, the tumor cells are necrotic. Middle (Ad-CMV-LacZ), after injection of the Ad-CMV-LacZ vector, neither the muscle nor the tumor are necrotic.

Tables

  • Figures
  • Table 1

    Characterization of percentage of cells positive for the CAR, αvβ3, and αvβ5 receptors as measured by FACS analysis and study of infectivity of cells by Ad-CMV-LacZ Vector at 20 MOI as measured by β-galactosidase assay (X-Gal)

    αvβ3, αvβ5, and CAR receptor levels were measured by mouse monoclonal antibodies, and the FITC-conjugated antimouse antibody was used to stain the cells. Then, FACS analysis was used to detect the percentage of the receptor-positive cells (n = 2). For infectivity, cells were exposed to virus in serum-free medium for 90 min at 20 MOI and incubated for 48 h in culture medium. Then, cells were stained by X-Gal analysis (n = 2).
    αvβ3αvβ5CARβ-Gal
    EJ83 ± 882 ± 595 ± 895 ± 8
    J8256 ± 678 ± 780 ± 1088 ± 10
    Skov-364 ± 691 ± 887 ± 785 ± 11
    Ovcar-548 ± 757 ± 588 ± 1065 ± 8
    Hey81 ± 596 ± 10010 ± 4
    CCD63 ± 893 ± 429 ± 570 ± 9
  • Table 2

    Comparison of β-galactosidase levels in cell line exposed to Ad-CMV-LacZ or Ad-Lp-LacZ (ONPG, OD)

    Cells were exposed in serum-free conditions for 90 min at 20 MOI. After 48 h of incubation in culture medium, the level of the β-galactosidase (ONPG) in each cell line was measured by optical density, as outlined in “Materials and Methods” (n = 2).
    Ad-CMV-LacZAd-Lp-LacZRatio of CMV/Lp
    EJ1.1 ± 0.20.9 ± 0.11.2
    J821.0 ± 0.10.4 ± 0.12.5
    Skov-30.9 ± 0.10.4 ± 0.12.2
    Ovcar-50.9 ± 0.10.4 ± 0.12.2
    CCD0.9 ± 0.10.1 ± 0.019
  • Table 3

    Percentage of cells in explant cultures of ovarian cancer cells and normal peritoneal cells which score positive for β-galactosidase after exposure to the Ad-CMV-LacZ and the Ad-Lp-LacZ vectors

    Samples of primary tumor, metastatic tumor, and normal peritoneum were cut into small pieces. These pieces were then digested with collagenase to produce tissue disaggregation, and the resulting cells were cultured in RPMI 1640 with 10% NBCS. All experiments were performed at 90% confluence. Samples of ascites were divided into the T25 flasks directly and washed to remove debris after cell attachment. Cells were infected in the flasks for 90 min, and after 48 h of incubation, the positive cells were measured by X-Gal staining or FACS.
    AscitesPrimary tumorMetastatic tumorNormal peritoneum
    Ad-CMV-βgal X-Gal 50–80%50–90%45–85%60–80%
    FACS 95%94%94%
    Ad-LP-βgal X-Gal 10–35%15–60%15–45%1–4%
    FACS 39%83%38%
    CMV/LP ratio FACS 3/11/13/120–60/1
  • Table 4

    Cytotoxicity in monolayer culture of normal peritoneum and ovarian cancer cells after expression to Ad-Lp-CD and Ad-CMV-CD vectors and 5FC (percentage of cells killed)

    In Ad-CMV-CD- and Ad-Lp-CD-infected samples, 500 μm 5-FC were added and incubated for 5 days, then the percentage of cells killed was estimated by comparing the percentage of cells which had died in the infected and uninfected control flasks.
    Ad-CMV-CDAd-Lp-CD
    Ascites98%85%
    Metastatic tumor85%70%
    Primary tumor90%75%
    Normal peritoneum95%10%
  • Table 5

    Tumor growth in animals injected with adenoviral LP vectors (percentage of animals found to be positive for tumors)

    The SCID mice were injected with 40 million Ovcar-5 or Skov3 tumor cells, which had been infected previously in vitro with the Ad-Lp-LacZ vector or the Ad-Lp-CD vector. Starting on the second day, 500 mg/kg 5-FC was injected each day for 10 days. Animals were autopsied at 21 days after tumor cell injection, and the presence or absence of tumor nodules in the peritoneal cavity was assessed.
    Ad-Lp-LacZ-infectedAd-Lp-CD-infected
    Ovcar-5 (100 MOI)10/10 (100%)0/10 (0%)
    Skov3 (80 MOI)5/5 (100%)0/5 (0%)
PreviousNext
Back to top
Cancer Research: 61 (11)
June 2001
Volume 61, Issue 11
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Use of the l-Plastin Promoter for Adenoviral-mediated, Tumor-specific Gene Expression in Ovarian and Bladder Cancer Cell Lines
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Use of the l-Plastin Promoter for Adenoviral-mediated, Tumor-specific Gene Expression in Ovarian and Bladder Cancer Cell Lines
Xue Yan Peng, Jong Ho Won, Thomas Rutherford, Takuma Fujii, Daniel Zelterman, Giuseppi Pizzorno, Eva Sapi, John Leavitt, Barry Kacinski, Ronald Crystal, Peter Schwartz and Albert Deisseroth
Cancer Res June 1 2001 (61) (11) 4405-4413;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Use of the l-Plastin Promoter for Adenoviral-mediated, Tumor-specific Gene Expression in Ovarian and Bladder Cancer Cell Lines
Xue Yan Peng, Jong Ho Won, Thomas Rutherford, Takuma Fujii, Daniel Zelterman, Giuseppi Pizzorno, Eva Sapi, John Leavitt, Barry Kacinski, Ronald Crystal, Peter Schwartz and Albert Deisseroth
Cancer Res June 1 2001 (61) (11) 4405-4413;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • INTRODUCTION
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • The Biological and Biochemical Effects of CP-654577, a Selective erbB2 Kinase Inhibitor, on Human Breast Cancer Cells
  • Novel Mechanisms of Apoptosis Induced by Histone Deacetylase Inhibitors
  • Phosphatidylinositol 3′-Kinase Is Required for Growth of Mast Cells Expressing the Kit Catalytic Domain Mutant
Show more Experimental Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement